Treatment of cancer

Rutherford Health Secures Loan Facility to Drive Forward Proton Beam Therapy

Retrieved on: 
Friday, October 18, 2019
Health sciences, Health, Proton, Proton therapy, Radiation therapy, Articles, PROTON Holdings, Therapy, Treatment of cancer, Proton Partners International

The nature of the Impact-Linked Pricing structure means Rutherford can enjoy more favourable loan terms aspatientnumbers increase at the company's three cancer centres in the UK, which offer proton beam therapy and a wide range of advanced cancer services.

Key Points: 
  • The nature of the Impact-Linked Pricing structure means Rutherford can enjoy more favourable loan terms aspatientnumbers increase at the company's three cancer centres in the UK, which offer proton beam therapy and a wide range of advanced cancer services.
  • "We are delighted to have secured this forward thinking facility with Triple Point which shares our goal of widening access to the most advanced cancer treatments.
  • Structuring a loan facility in a way that encourages accessibility to our services is a progressive approach.
  • "This investment will lead to the continued expansion of our services, particularly proton beam therapy.

Prostate Cancer - Global Market Outlook 2017-2026 - Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities

Retrieved on: 
Thursday, October 17, 2019
RTT, Anatomy, Medicine, Clinical medicine, Histopathology, Prostate cancer, Prostate, Cancer, Treatment of cancer, Management of prostate cancer, Prostate-specific antigen

DUBLIN, Oct. 17, 2019 /PRNewswire/ -- The "Prostate Cancer - Global Market Outlook (2017-2026)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Oct. 17, 2019 /PRNewswire/ -- The "Prostate Cancer - Global Market Outlook (2017-2026)" report has been added to ResearchAndMarkets.com's offering.
  • The Global Prostate Cancer market is growing at a CAGR of 10.3% during the forecast period.
  • Prostate cancer is one of the most ordinary types of cancer in men which is caused by the irregular growth of tissues in the prostate gland that produce seminal fluid.
  • For patients with cancer, biological therapies may be used to treat the cancer itself or the side effects of other cancer treatments.

Cellectar Presents Poster at the Cancer Research UK-AACR Joint Conference on Engineering and Physical Sciences in Oncology

Retrieved on: 
Tuesday, October 15, 2019
Stem cells, Carcinogenesis, Cancer stem cell, Treatment of cancer

The PDCs also demonstrated potent activity against the tumor cells with inhibitory concentrations in the low nanomolar range.

Key Points: 
  • The PDCs also demonstrated potent activity against the tumor cells with inhibitory concentrations in the low nanomolar range.
  • Cellectar's product candidates are built upon a patented delivery and retention platform that utilizes optimized phospholipid ether-drug conjugates (PDCs) to target cancer cells.
  • The PDC platform selectively delivers diverse oncologic payloads to cancerous cells and cancer stem cells, including hematologic cancers and solid tumors.
  • Cellectar Biosciences is focused on the discovery, development and commercialization of drugs for the treatment of cancer.

Susan G. Komen® Urges Commitment to Conquer Metastatic Breast Cancers

Retrieved on: 
Monday, October 14, 2019
Research, Women, Genetics, Stem cells, Biotechnology, Consumer, Health, Science, Oncology, Other Science, Medicine, Health, RTT, Medical specialties, Metastatic breast cancer, Breast cancer, Susan G. Komen for the Cure, Metástasis, Biopsy, Treatment of cancer, Cancer, Breast cancer awareness

Metastatic breast cancer also called Stage IV breast cancer is the most advanced stage of breast cancer.

Key Points: 
  • Metastatic breast cancer also called Stage IV breast cancer is the most advanced stage of breast cancer.
  • If scientists can unlock the potential of liquid biopsies for metastatic breast cancer, doctors may then be able to use small samples of blood to detect metastatic disease even before symptoms arise, monitor metastatic breast cancer treatment response and adjust therapies, and develop more personalized treatment plans for metastatic breast cancer patients.
  • Kelly Shanahan, a former physician and current metastatic breast cancer patient and advocate, added, Komen has stepped up its commitment to discovering breakthroughs for metastatic breast cancer and supporting those living with the disease today.
  • Susan G. Komen is the worlds leading nonprofit breast cancer organization, working to save lives and end breast cancer forever.

Clovis Oncology Announces Rubraca®▼ (rucaparib) Now Available for Women with Relapsed Ovarian Cancer in England Through the Cancer Drugs Fund

Retrieved on: 
Friday, October 11, 2019
Biotechnology, Pharmaceutical, Oncology, Health, Genetics, Clinical trials, RTT, Oncology, Gynaecological cancer, Cancer, Medical specialties, Health, Gynaecology, Ovarian cancer, Treatment of cancer, Ovarian disease, CA-125, Rubraca® (rucaparib), Clovis Oncology

Many women with relapsed ovarian cancer know that they are facing a future of managing their disease as a chronic illness.

Key Points: 
  • Many women with relapsed ovarian cancer know that they are facing a future of managing their disease as a chronic illness.
  • For too long ovarian cancer treatment options beyond chemotherapy or surgery have been limited, and todays announcement means that women with ovarian cancer have more choice in their treatment than ever before, said Annwen Jones, Chief Executive of Target Ovarian Cancer, a United Kingdom ovarian cancer charity.
  • Target Ovarian Cancer has long campaigned for better treatment for women with ovarian cancer and we are delighted to see this latest development.
  • This represents a significant step in the effective management of relapsed ovarian cancer in the NHS in England.

Following NCCN Guidelines for Metastatic Breast Cancer Results in Lower Costs for Patients, According to New Study

Retrieved on: 
Thursday, October 10, 2019
RTT, Hereditary cancers, Health, Breast cancer, National Comprehensive Cancer Network, NCCN, Metastatic breast cancer, Cancer, Treatment of cancer, Cowden syndrome

"We found about one in five women received an anticancer treatment that wasn't listed within the NCCN Guidelines.

Key Points: 
  • "We found about one in five women received an anticancer treatment that wasn't listed within the NCCN Guidelines.
  • Those women were responsible for higher out-of-pocket costsincluding deductibles, coinsurance, and copaymentsin the year following their metastatic breast cancer diagnosis than those receiving an anticancer treatment listed within the guidelines.
  • Treatment regimens were matched to the version of the NCCN Guidelines for Breast Cancer that were available at the exact treatment date.
  • The National Comprehensive Cancer Network (NCCN) is a not-for-profit alliance of 28 leading cancer centers devoted to patient care, research, and education.

Datar Cancer Genetics Announces Positive Results With 42.9% Objective Response Rate, and 90.5% Disease Control Rate in Heavily Pre-treated Patients With Ultra-personalised Pan-cancer Treatment Protocol in the RESILIENT Trial

Retrieved on: 
Wednesday, October 9, 2019
RTT, Medicine, Health, Causes of death, Oncology, Cancer, Treatment of cancer, Progression-free survival, Precision medicine

The study achieved its primary and secondary end points of Objective Response Rate, Progression Free Survival and Disease Control Rate respectively.

Key Points: 
  • The study achieved its primary and secondary end points of Objective Response Rate, Progression Free Survival and Disease Control Rate respectively.
  • As a large proportion of all patients with advanced cancers ultimately progress towards this phase, life extending treatment options for these patients are urgently required.
  • RESILIENT is the world's first and only prospective Precision Oncology trial where drug combinations were selected on multi-analyte integration.
  • Datar is a leading cancer research corporation specialising in tumour analysis for better diagnosis, treatment decisions, and management of cancer.

Datar Cancer Genetics Announces Positive Results With 42.9% Objective Response Rate, and 90.5% Disease Control Rate in Heavily Pre-treated Patients With Ultra-personalised Pan-cancer Treatment Protocol in the RESILIENT Trial

Retrieved on: 
Wednesday, October 9, 2019
RTT, Medicine, Health, Causes of death, Oncology, Cancer, Treatment of cancer, Progression-free survival, Precision medicine

The study achieved its primary and secondary end points of Objective Response Rate, Progression Free Survival and Disease Control Rate respectively.

Key Points: 
  • The study achieved its primary and secondary end points of Objective Response Rate, Progression Free Survival and Disease Control Rate respectively.
  • As a large proportion of all patients with advanced cancers ultimately progress towards this phase, life extending treatment options for these patients are urgently required.
  • RESILIENT is the world's first and only prospective Precision Oncology trial where drug combinations were selected on multi-analyte integration.
  • Datar is a leading cancer research corporation specialising in tumour analysis for better diagnosis, treatment decisions, and management of cancer.

Precision Immunotherapy Innovations Transforming Human Health and Wellness

Retrieved on: 
Monday, October 7, 2019
Medical specialties, Medicine, Clinical medicine, Immunology, Monoclonal antibodies, Cancer treatments, Antibody, Glycoproteins, Bispecific monoclonal antibody, Immune system, Cancer, Treatment of cancer

There are numerous companies developing immunotherapy approaches to treat cancer, autoimmune and several other diseases.Current study describes some of the recent advances in immunotherapy, mostly cancer.

Key Points: 
  • There are numerous companies developing immunotherapy approaches to treat cancer, autoimmune and several other diseases.Current study describes some of the recent advances in immunotherapy, mostly cancer.
  • These include refined cell therapies, stem cell applications in cancer treatment, monoclonal, polyclonal and bispecific antibodies.Some of exciting technologies like trispecific and multispecific fusion proteins and antibody derivatives are also covered.
  • ReportLinker is an award-winning market research solution.
  • Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

Precision Immunotherapy Innovations Transforming Human Health and Wellness, 2019 Report - ResearchAndMarkets.com

Retrieved on: 
Monday, October 7, 2019
Health, Other Health, Medical specialties, Medicine, Clinical medicine, Immunology, Monoclonal antibodies, Bispecific monoclonal antibody, Immunotherapy, Treatment of cancer, Cancer, Antibody, Shimon Slavin

The "Precision Immunotherapy Innovations Transforming Human Health and Wellness" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Precision Immunotherapy Innovations Transforming Human Health and Wellness" report has been added to ResearchAndMarkets.com's offering.
  • There are numerous companies developing immunotherapy approaches to treat cancer, autoimmune and several other diseases.
  • The current study describes some of the recent advances in immunotherapy, mostly cancer.
  • These include refined cell therapies, stem cell applications in cancer treatment, monoclonal, polyclonal and bispecific antibodies.